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Inflammatory arthritis can be reined in by
CpG-induced DC–NK cell cross talk
Hsin-Jung Wu,1 Heloisa Sawaya,5 Bryce Binstadt,1,2 Margot Brickelmaier,4
Amanda Blasius,6 Leonid Gorelik,4 Umar Mahmood,5 Ralph Weissleder,5
John Carulli,4 Christophe Benoist,1,3 and Diane Mathis1,3
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on Immunology and Immunogenetics, Joslin Diabetes Center, 2Rheumatology Program, Children’s Hospital Boston,
of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA 02115
4Biogen Idec, Inc., Cambridge, MA 02142
5Center for Molecular Imaging Research, Massachusetts General Hospital, Charlestown, MA 02114
6Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63101

Unmethylated CpG-oligodeoxynucleotides (ODNs) are generally thought of as potent adjuvants
with considerable therapeutic potential to enhance immune responses against microbes
and tumors. Surprisingly, certain so-called stimulatory CpG-ODNs strongly inhibited the
effector phase of inflammatory arthritis in the K/BxN serum transfer system, either preventively or therapeutically. Also unexpected was that the inhibitory influence did not depend
on the adaptive immune system cells mobilized in an immunostimulatory context. Instead,
they relied on cells of the innate immune system, specifically on cross talk between CD8␣ⴙ
dendritic cells and natural killer cells, resulting in suppression of neutrophil recruitment to
the joint, orchestrated through interleukin-12 and interferon-␥. These findings highlight
potential applications of CpG-ODNs and downstream molecules as antiinflammatory agents.
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Abbreviations used: Ab, antibody; AP, alkaline phosphatase;
CAE, chloroacetate esterase
substrate; DT, diphtheria toxin;
DTR, DT receptor; GPI, glucose-6-phosphate-isomerase;
HE, hematoxylin and eosin;
HEK, human embryonic kidney; IC, immune complex;
IDO, indoleamine 2,3-dioxygenase; IKDC, interferon-producing killer dendritic cell; OD,
optimal density; ODN, oligodeoxynucleotide; PAM, pathogenassociated molecule; pDC,
plasmacytoid DC; PGN, peptidoglycan; RA, rheumatoid
arthritis; TLR, Toll-like
receptor.

The inflammatory arthritides are an important
health problem—rheumatoid arthritis (RA) affects ⵑ1% of the world’s population. Genetic
factors are known to have a substantial impact
on the incidence and progression of RA, but
the low concordance rate of this disease in
monozygotic twins (ⵑ20%) raises the possibility of environmental factors also exerting a crucial influence (1). Indeed, there have been many
reports of correlations between viral or bacterial
infections and the onset of RA in humans (2).
Furthermore, several animal models of inflammatory arthritis are initiated by one or another
microbial constituents (3).
Cells of the innate immune system detect
the intrusion of pathogens by recognizing conserved sequence motifs embedded within molecules expressed by the intruders (4). Some
examples of such motifs are LPS, peptidoglycans (PGNs), double- and single-stranded RNAs,
and unmethylated DNA CpG motifs (CpGs).
These “pathogen-associated molecules (PAMs)”
are specifically recognized by sets of receptors, the best characterized of which are the
toll-like receptor (TLR) family members (4, 5).
The online version of this article contains supplemental material.
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PAMs and their receptors provide powerful
molecular probes for assessing a potential impact
of microbes on the initiation and progression
of arthritis. Indeed, administration of PAMs
promoted disease development in several mouse
models of arthritis (6–8).
Given their potential importance, we decided
to explore the roles of TLRs and their ligands
in the K/BxN mouse model of inflammatory
arthritis, which is a particularly convenient system for performing mechanistic dissection. This
model has the additional advantage of not requiring adjuvants, which often contain TLR
ligands, for disease induction, thereby avoiding
potential problems of synergy. K/BxN mice express a transgene-encoded TCR that is reactive
to a self-peptide derived from the ubiquitously expressed enzyme glucose-6-phosphate-isomerase
(GPI), presented by the MHC class II molecule
Ag7 (3). Beginning at 3–5 wk of age, K/BxN
mice spontaneously develop an autoimmune/
inflammatory disease with many features in common with those of human RA (3). Conveniently,
transfer of serum from arthritic mice into healthy
nontransgenic animals induces arthritis in a highly
synchronized and reproducible fashion (3). Importantly, this system does not require LPS to

Supplemental Material can be found at:
http://jem.rupress.org/content/suppl/2007/07/22/jem.20070285.DC1.html

1911

Downloaded from jem.rupress.org on September 13, 2011

The Journal of Experimental Medicine

3Division

Published July 23, 2007

be effective, unlike collagen antibody–induced arthritis (7),
again, simplifying the interpretation of results. Arthritis is a
very complex, polygenic, and multifactorial disorder, so a
major attraction of this serum-transfer system is that it allows
one to focus on the inflammatory effector phase of disease,
without the complicating influences of the autoimmune initiation phase.
To delineate points of potential environmental impact
specifically in the arthritis effector phase, we examined the
influence of selected TLRs and TLR ligands in the K/BxN
serum-transfer system. Results from these experiments confronted us with two surprises: a potent antiinflammatory
effect exerted by so-called stimulatory TLR9 ligands, and

a mechanism that relies solely on cells of the innate immune
system, without the requirement for cells of the adaptive
immune system seen with other CpG-mediated immunotherapeutic activities.
RESULTS
Certain CpGs inhibit K/BxN serum-transferred arthritis
As a first approach to exploring the role of TLRs and their
ligands in the effector phase of inflammatory arthritis, we
screened several TLRs for the ability to influence K/BxN
serum-transferred disease. As might have been expected (7, 8),
LPS exacerbated arthritis development in B6 mice when administered i.p. 2 d before K/BxN serum transfer (Fig. 1 A),

Downloaded from jem.rupress.org on September 13, 2011
Figure 1. Some CpGs inhibit K/BxN serum-transferred arthritis. (A) Mean ankle thickening (left) or clinical score (right) of mice injected i.p. with
50 g LPS, 10 nmol CpG-ODN (ODN1668), or nothing on day −2 and with 100 l of K/BxN serum i.p. on day 0. The black and white arrows indicate administration of serum and various TLR ligands, respectively. Representative of two independent experiments (n ⫽ 3 mice/group). (B) Ankle thickening of mice
treated with the optimum serum dose (150 l K/BxN serum on day 0 and 2), together with stimulatory ODNs (ODN1668, ODN1826, ODN1758, ODN1643,
and ODN1585), a suppressive ODN (H154), or nothing on day 0 and 2. Except for ODN1558, all bases of the ODNs used in this paper were phosphorothioate modified. Effects were evaluated as disease incidence, mean of maximal clinical score, and mean of maximal ankle thickening. CpG dinucleotides are
underlined. (C) Mean of ankle thickening (left) or clinical score (right) of mice treated with 150 l K/BxN serum on day 0 and 2, either with or without
ODN1668 on day 4 and 6 (n ⫽ 3). The black and white arrows indicate administration of serum and ODN1668, respectively. Representative of two independent experiments.
1912
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whether assayed as ankle thickening (left) or as a clinical score
(right). Preparations of PGNs, Pam3Cys4, and poly I:C had a
similar effect when tested under the same protocol (unpublished data). In contrast, and surprisingly, injection of the CpG
oligodeoxynucleotide (ODN) 1668 (Fig. 1 B) severely inhibited
development of disease (Fig. 1 A). None of the TLR ligands
was able to induce arthritis when injected alone i.p. (unpublished
data), in contrast to what has been reported for intraarticular
injection of unmethylated CpGs (6), for example.
Interestingly, although some CpG-ODNs were capable
of inhibiting K/BxN serum-transferred arthritis, others were

not (Fig. 1 B). ODNs 1826 and 1758 also had a suppressive
effect, although in the latter case it was only a moderate
one; ODNs 1585, D19 (unpublished data), 1643, and H154
had no detectable influence. The two CpG-ODNs with the
strongest influence on disease development are the most similar in sequence, differing by only two nucleotides at the 3⬘
end. Both of these are so-called CpG-B-ODNs, which are
characterized by having one or more CpG sequences on a
fully phosphorothioate-modified backbone, and by being
particularly stimulatory for B cells (9). The ODNs with no
effect on arthritis included ones classified as CpG-B (1643);
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Figure 2. ODN1668 impacts early in arthritogenesis. (A) HE-stained ankle sections from mice 8 d after K/BxN serum transfer with or without
ODN1668. Bar, 0.25 mm. n ⫽ 2. (B) Serial ankle cryostat sections from B6 mice 8 d after K/BxN serum transfer with or without ODN1668. Stained with
anti-C3d Ab (i and iv), anti-IgG Ab (ii and v), or anti-GPI Ab (iii and vi). Arrow indicates the interface between the cartilage and articular cavity, where ICs
can accumulate. Bar, 0.25 mm. n ⫽ 2. (C) CAE-stained ankle sections from mice 1 d after K/BxN serum (200 l) transfer with or without ODN1668. Many
hypersegmented neutrophils with red cytoplasmic staining (white arrow) can be observed in the serum-treated group; in contrast, only resident mast
cells (black arrow) and normal loose connective tissue can be seen in the serum⫹CpG-treated group. Bar, 25 m. Results on the incidence of neutrophil
infiltration from six mice in each group are tabulated. (D) Mice were treated with PBS (i and ii) or CpG (iii and iv), followed 1 h later with Cy5.5 vascular
probe. 10 min after probe injection, 200 l of normal (i and iii) or K/BxN (ii and iv) serum was transferred. Confocal micrographs of hindpaws were obtained every 3 s for 5 min before and 10 min after serum injection. (left) Images taken at 10 min after serum injection. The mean maximal leakage rate
(right) was calculated by using the first derivative of rate curves generated by plotting the mean fluorescence intensity of individual confocal micrographs
obtained every 3 s after serum injection. Bar, 0.5 mm. n ⫽ 5 mice/group. Results are plotted as the mean ⫾ the SEM.
JEM VOL. 204, August 6, 2007
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CpG-A, with their mixed phosphorothioate/phosphodiester
backbone, central CpG-containing palindrome, and terminal
polyG motifs (1585); and CpG-N, which can neutralize the
effects of immunostimulatory CpGs, including their induction
of arthritis in certain contexts (10). The one CpG-N assessed,
H154, was also unable to suppress the negative effect of CpG-Bs
on arthritis in our system (unpublished data).
ODN1668 was optimally effective at inhibiting K/BxN
serum-transferred arthritis when introduced coincident with,
or shortly before injection of, the arthritogenic serum. However, it also had efficacy in a therapeutic mode, when administered as long as 4 d after serum transfer (Fig. 1 C). It did not
seem to revert symptoms to the predisease state, but rather to
stop them in their tracks.

1914

Figure 3. The molecular elements required for ODN1668-mediated
protection. (A) Ankle thickening of WT or TLR9-KO mice treated i.p.
with 10 nmol of ODN1668 and 150 l of K/BxN serum on day 0 and 2 or
with serum alone. Results are plotted as the mean ⫾ the SEM. n ⫽ 3–4/
group. IL-12 and IFN-␥ are critical for the CpG-mediated inhibitory effect.
(B) Mean ankle thickening of IL-12p35⫺/⫺ and IFN-␥⫺/⫺ mice treated with
K/BxN serum alone or together with ODN1668. Representative of two independent experiments. n ⫽ 3 mice/group. The black and white arrows indicate administration of serum and ODN1668, respectively. (C) Various ODNs
were injected i.p. into B6 mice, and the spleens were collected 4 h later. Fold
induction of IFN-g and IL-12p40 transcripts in spleens were quantitated by
semiquantitative RT-PCR as described in the Materials and methods. Results
were compiled from three independent experiments with four mice per
group. (D) Serum levels of IL-12 and -23 were measured at the indicated
time points after ODN1668 injection via ELISA. n ⫽ 2 mice/group for each
time point. IFN-␥ induction is a driving element. (E and F) B6, IL-12p35⫺/⫺,
or IFN-␥⫺/⫺ mice were treated with ODN1668 for 4 h, and fold induction
of cytokine transcripts in splenocytes was determined as in D, shown as
IL-12p35⫺/⫺ versus WT (E) or IFN-␥⫺/⫺ versus WT (F). Results were compiled
from four independent experiments with 6–7 mice/group.

coadministration of ODN1668 (Fig. 2 D, right). Injection of
this CpG in the absence of serum did not provoke vessel leakage
(Fig. 2 D, compare iii and i). Because the vascular permeability
ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
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CpG-ODNs operate over a time window between
the opening of the vasculature and the influx of
inflammatory cells
Mechanisms of pathogenesis in the K/BxN serum-transfer
system have been extensively dissected (3, 8, 11–14). Quite
similar to a reverse-passive Arthus reaction, arthritis development entails the following, sequentially: GPI–anti-GPI
immune complex (IC) formation; activation of inflammatory
and probably endothelial cells; induction of macromolecular
leakage in joint vessels; complement activation; inflammatory
cell influx; an amplification loop resulting in massive cytokine
production; leukocyte recruitment and synovial hyperplasia;
and, ultimately, joint destruction. To delineate precisely when
CpGs impinge on the arthritogenic process, we evaluated
their effect on the different disease subphenotypes that had
been instrumental in constructing this pathogenetic scenario.
Consistent with the observed dampening of inflammation
signaled by a reduction in ankle swelling, hematoxylin and
eosin (HE)–stained ankle sections taken from mice 8 d after
coadministration of K/BxN serum and ODN1668 revealed
an absence of synovial hyperplasia and leukocyte infiltration
(Fig. 2 A). IC deposition and complement activation, detected as GPI/IgG/C3d costaining on cryostat sections, was
also absent from the ankles of serum/CpG-cotreated animals,
although there was weak GPI binding at the cartilage–articular cavity interface (Fig. 2 B), as expected (15). Neutrophil
recruitment was assayed 1 d after serum ⫾ CpG administration by staining ankle sections with HE and chromogenic
chloroacetate esterase substrate (CAE), which specifically identifies granulocytes/neutrophils. At this time point, the disease
is still at an early stage, so only 3 out of 6 mice injected with
serum alone showed infiltration of neutrophils; in contrast,
none of the animals coinjected with ODN1668 exhibited
neutrophil recruitment (Fig. 2 C).
However, in serum/CpG-cotreated animals the typical
vascular permeability to macromolecules that can be visualized
by laser-scanning confocal microscopy of an immobilized heel
in vivo in real time, subsequent to injection of a Cy5.5-labeled
graft copolymer imaging reagent, was present (Fig. 2 D, left;
compare iv and ii). Specifically, the maximum rate of leak was
the same in K/BxN serum-transferred mice with or without
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provoked by serum transfer depends on ICs (11), it would
appear that ODN1668 did not compromise GPI/anti-GPI IC
formation per se, which is consistent with the observation of
indistinguishable anti-GPI antibody (Ab) titers in the blood in
the presence or absence of this ODN (unpublished data).
Thus, the window within which CpGs impinge on the
unfolding of arthritis in this system is delimited on one side
by opening of the vasculature (⬎2 min after serum injection)
and on the other side by inflammatory cell influx subsequent
to IC deposition, and the consequent activation of complement (⬍24 h after injection).

CpG-mediated inhibition of arthritis requires IL-12
and IFN-␥
To begin dissecting the molecular mechanisms underlying
the dampening of K/BxN serum-transferred arthritis by
ODN1668, we screened disease inhibition in several mouse
strains deficient in the expression of cytokines, particularly
some of those previously reported to operate downstream of
TLR9 signaling. These experiments were, of course, limited
to an assessment of strains that could develop disease in the
first place, i.e., not those devoid of IL-1 or TNF-␣.
Both IL-12p35 and IFN-␥ (Fig. 3 B) were required for
ODN1668 to exert its suppressive effect, as transfer of serum
plus CpG, versus serum alone, into the corresponding KO
strains provoked arthritis with the same kinetics and severity,
i.e., with no sign of a CpG-mediated inhibitory effect. In
contrast, IL-6 was not needed for effective inhibition (unpublished data).
JEM VOL. 204, August 6, 2007
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The CpG-mediated inhibitory effect is signaled
through TLR9
CpGs are known to exert their immunostimulatory effects
through binding to TLR9 (16). Yet, because it has been hypothesized that other receptors might be involved in CpGinduced activation (17), and because binding of ODNs 1668
and 1826 to TLR9 has generally been associated with stimulatory rather than suppressive influences (9), we wished to
verify that CpG-mediated inhibition of K/BxN serum-transferred arthritis actually does result from their signaling through
TLR9. First, TLR9-transfected human embryonic kidney
(HEK) 293 cells were stimulated with the various ODNs
whose properties are depicted in Fig. 1 B, and induction of a
luciferase reporter gene driven by NF-B–responsive regulatory elements was measured. There was a clear correlation
between the strength of the TLR9-transduced signal and its
disease-dampening capacity, ODNs 1668 and 1826 being
strongest according to both criteria, ODN1758 being intermediate, and ODN1643 and H154 being the weakest (Fig.
S1, left, available at http://www.jem.org/cgi/content/full/
jem.20070285/DC1). None of the CpG-ODNs elicited a
signal in control TLR2-transfected HEK-293 cells (Fig. S1,
right). Second, according to data on KO mice, TLR9 was
not required for arthritis to develop in response to K/BxN
serum transfer; however, it was needed for the ODN1668induced inhibition of this process (Fig. 3 A).

There was an excellent correlation between the ability of
a given ODN to inhibit arthritis and its capacity to induce
IFN-␥ and IL-12p40 gene expression in spleens of recipient
mice 4 h after injection (compare Fig. 1 B and Fig. 3 C). In
contrast, splenocyte transcription of several other cytokine
genes (e.g., TNF-␣, IL-15, IL-2, and IL-1) demonstrated no
such correlation (unpublished data). The increase in IL-12p40
expression was associated with a transient augmentation in
secretion of the IL-12 cytokine, itself, rather than of IL-23,
which also contains the p40 subunit, as indicated by ELISA
measurements of serum-cytokine levels (Fig. 3 D).
IL-12p40 expression was important for induction of IFN-␥
transcription, although some increase in transcript levels was

Figure 4. Administration of IFN-␥ prevents arthritis development
and blocks neutrophil recruitment by binding to their IFN-␥ receptors.
(A) Mean ankle thickening of mice treated with 150 l K/BxN serum
on day 0 and 2, together with daily i.p. injection of 50 g IFN-␥ or vehicle
control (10% FBS-RPMI) for 7 d. Results were compiled from two independent experiments. n ⫽ 4 mice/group. (B) Purified neutrophils from WT
B6 (i, ii, and iii) or IFN-␥R KO (iv) mice were treated with IFN-␥ (iii and iv)
or not (i and ii), and were transferred into arthritic B6 mice. Bar, 0.5 mm.
Results shown are images of neutrophils (green) in the inflamed ankles.
(C) The bar graphs depict averages of neutrophil number minus background (no serum group [B, i]; mean number is 5.3 from 4 mice). n ⫽ 4–6
for each group. Error bars represent the SD.
1915
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The case for DC–NK cell crosstalk
The combined requirement for IL-12 and IFN-␥, and their
interdependent expression, evoke recent findings on the

Figure 5. DCs and NK cells are critical players in CpG-mediated
inhibition. (A) Mice were treated with PBS, 10 nmol ODN1643, or 10 nmol
ODN1668 on day 0 and 2. Spleens were harvested on day 8, and cell types
1916

were identified by their surface markers as follows: T cells
(CD3⫹NK1.1⫺), NKT cells (CD3⫹NK1.1⫹), NK cells (CD3⫺NK1.1⫹), B cells
(B220⫹CD11c⫺), plasmacytoid DCs (pDCs; B220⫹CD11cint), conventional
DCs (cDC; B220⫺CD11chigh), macrophages (Mac; Gr1⫺CD11b⫹), heterogeneous myeloid cells (HMCs; Gr1dullCD11b⫹), and neutrophils
(Gr1highCD11b⫹). A dot plot from one representative mouse out of three is
shown. The percentage of total live cells (mean ⫾ the SD) from 3 mice is
indicated. Representative of two experiments. (B) Same as in A; absolute
cell number is shown (mean ⫾ the SD). Total splenocyte counts were
as follows: in PBS-treated mice, 128, 84, and 84 million; in ODN1643injected mice, 100, 68, and 96 million; and in ODN1668-injected mice,
328, 384, and 328 million. All cell types, except for T cells, are statistically
significant (P ⬍ 0.05, Student’s t test) in both the PBS versus ODN1668
and ODN1643 versus ODN1668 comparisons. (C) B6 mice were injected
i.p. with ODN1668 or PBS, and 4 h later, spleens were harvested and
sorted into various cell types as defined in A; except for DCs, NK cells
were excluded before sorting into the Mac and HMC populations; the DC
population includes both the plasmacytoid and conventional subsets. Fold
induction of IL-12p40 and IFN-g. Transcripts in various cell types were
measured by RT-PCR as in Fig. 3 C. Results shown are the average of fold
inductions from two independent experiments with a pool of 3 spleens/
group. (D) Mice were injected i.p. with ODN1668, and spleens were harvested after 1, 2, or 4 h. NK cells, pDC, CD8␣⫹ DCs, and CD8␣⫺ DCs were
sorted (Figs. S2 and S9) and examined for their IL-12p40 and IFN-␥ transcript induction. Results shown are the average fold inductions from two
independent experiments. (E) Splenocytes from TLR9⫺/⫺ CD45.2 and WT
CD45.1 congenic mice were mixed at a 1:1 ratio and cultured with
ODN1668 for 2 or 4 h. TLR9⫺/⫺ and WT DC or NK cells were sorted based
on their CD45 alleles, and were examined for their IL-12p40 and IFN-␥
transcript induction. The results shown are the average of fold inductions
from two independent experiments. Figs. S2 and S9 are available at
http://www.jem.org/cgi/content/full/jem.20070285/DC1.
ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
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still evident in its absence (Fig. 3 E); IFN-␥ expression also
promoted the induction of IL-12 transcription (Fig. 3 F). As
discussed below, this mutual dependence might be taken as
evidence of a feed-forward loop.
Strikingly, systemic administration of IFN-␥ was an effective inhibitor, by itself, of serum-transferred arthritis, arguing
that systemic mechanisms are probably in play (Fig. 4 A). Because CpG blocked neutrophil accumulation in the joints,
and IFN-␥ was identified as the downstream effector of CpG,
we next examined whether IFN-␥ prevented joint inflammation by acting directly on neutrophil migration. Using a novel
laser-scanning, time-lapse, intravital imaging system, we found
that IFN-␥ administration did inhibit recruitment of WT
neutrophils into inflamed joints; however, this inhibition was
lost when neutrophils from IFN-␥R KO animals were used
(Fig. 4, B and C). Note that the absence of IFN-␥R on neutrophils did not, in and of itself, influence their migration
into the joint under the influence of serum alone (unpublished data). Therefore, IFN-␥ directly blocks neutrophil
migration by binding to their IFN-␥ receptors. Without neutrophil migration, arthritis cannot set in.
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mouse strain wherein DCs can be killed off by diphtheria
toxin (DT) treatment of transgenic animals expressing the
simian DT receptor (DTR) primarily on DCs, under the dictates of the mouse CD11c promoter (21). These mice were
found to lack all CD11c⫹ DC populations, which reduced
their capacity to control microbial infections. Because it was
reported that the DC compartment began to reemerge 3–5 d
after DT treatment, we needed to modify our protocol as per
Fig. 6 A (i) to enable us to assay arthritis induction and CpGmediated inhibition of it during this short time frame. The
DC populations were strongly reduced by this protocol,
whereas other cell-types, e.g., NK, T, and B cells, were not
(Fig. 6 A [ii] and not depicted). Loss of DCs during this time
frame had no detectable effect on arthritis progression; however, it did strongly compromise the inhibitory effect of
ODN1668 (Fig. 6 A, iii).
IL-15–deficient mice have a strong deficiency in NK cells,
but also have deficits in some populations of T lymphocytes,
particularly memory T and NKT cells (Fig. S4 A, available at
http://www.jem.org/cgi/content/full/jem.20070285/DC1)
(22). However, the CpG-induced, arthritis-inhibitory effect
was independent of all ␣/␤ T and B cell populations, as was
evident with mice carrying a mutation of the TCR␣ locus
or in animals lacking B cells caused by the MT mutation
(Fig. S5). IL-15 KO mice were fully susceptible to K/BxN
serum-transferred arthritis, but not to inhibition of disease
by ODN1668 (Fig. 6 B, left). Because it was recently reported that mice lacking IL-15 also have defects in some DC
populations (although we did not find a numerical deficit;
Fig. S4) (23), we tried a second strategy for eliminating NK
cells. The polyclonal Ab anti–asialo-GM1 will deplete NK
cells, though there are some reports that a subset of CD8⫹
T cells may be removed as well. Again, however, we know
that T cells are not required for the CpG-induced suppression of arthritis (Fig. S5, middle). Anti–asialo-GM1 treatment
reduced NK cells to ⵑ30% of the normal level, although not
depleting the T or NKT cell populations (Fig. S4 B), but did
not affect serum-induced arthritis. Such treatment did, on the
other hand, compromise the ability of ODN1668 to inhibit
disease unfolding (Fig. 6 B, right). Together, these two sets
of findings on NK cell depletion argue that this cell type has
a critical role in CpG-mediated inhibition of serum-transferred arthritis. Again, consistent with the proposed scenario
of DC–NK cell cross talk were results on cytokine gene expression in the DTR and IL-15 KO mice; a strong reduction
in both IL-12 and IFN-␥ expression in the former case, with
residual levels probably being attributable to incomplete DC
depletion (Fig. 6 C, left), but a drop in only IFN-␥ transcripts
in the latter case (Fig. 6 C, right).
DISCUSSION
The therapeutic potential of CpGs has excited great interest of
late (24). Their potent adjuvant activity can be applied to eliciting more effective immune responses to infectious agents or
tumors. Their ability to bias responses in a TH1 direction can
be harnessed to redirect pathogenic TH2 responses, e.g., in the
1917
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importance of the interplay between dendritic and NK cells,
and the molecular crosstalk between them, in initiating responses by the innate immune system (18, 19). On one hand,
DCs can prime, further the activation of, augment the expansion of, and enhance the activities of NK cells through the
production of cytokines like IL-2, -12, -15, IFN-␣/␤, and
TNF-␣. On the other hand, mostly through the intermediary of IFN-␥, NK cells can enhance the differentiation, survival, and function of DCs, especially their expression of
costimulatory molecules and production of IL-12 and TNF-␣.
Because most of the studies responsible for these conclusions
were performed with cultured cells, the in vivo significance
remains somewhat controversial. Nevertheless, we hypothesized that such a scenario underlies the CpG-mediated inhibition of K/BxN serum-transferred arthritis, and set out to
test this notion.
As a first step, we performed a cytofluorimetric comparison of splenocytes from mice injected with PBS, the control
CpG 1643, or the arthritis-inhibitory CpG 1668. As detailed
in Fig. 5 (A and B), most of the examined cell populations
had increased in number by 8 d after ODN1668 injection, a
time point when the expansion of spleen cells was maximal
and the inhibitory effect on arthritis was clearly evident. In
particular, there was a striking overrepresentation of NK cells
(CD3⫺NK1.1⫹; top) augmenting 18-fold in number and rising fractionally from an average of 4.4–22%.
Next, we examined cytokine mRNA induction in the
different splenocyte populations (Fig. 5 C). The dominant
IL-12–producing cells 4 h after injection of ODN1668 were
DCs; NK cells were the major producers of IFN-␥, although
NKT and DCs also made low amounts.
In mice, splenic CD8␣⫹ and CD8␣⫺ DCs both express
TLR9, and both can be induced to secrete IL-12 after stimulation in culture with CpG (20). However, we found that in
vivo, CD8␣⫹, but not CD8␣⫺, DCs were the major cell type
responsible for CpG-induced IL-12 induction (Fig. 5 D and
Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20070285/DC1). Maximum expression of IL-12 occurred
at 1 h after CpG injection; in contrast, induction of IFN-␥
expression by NK cells maxed later at 4 h.
We next sought to determine where TLR9 needed to be
expressed for DCs to turn up IL-12 expression and NK cells
to up-regulate IFN-␥ transcription. CD45.2 TLR9⫺/⫺ splenocytes were mixed 1:1 with splenocytes from WT CD45.1
congenic B6 mice, and the mixture was stimulated with
CpG. TLR9⫺/⫺ DCs were not induced to express IL-12 (Fig.
5 E, left); a similar result was obtained by staining for intracellular IL-12 (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20070285/DC1). There was no difference in IFN-␥ induction in TLR9⫺/⫺ versus WT NK cells
(Fig. 5 E, right). Thus, CpG engagement on CD8␣⫹DCs
appears to be the gateway for this antiinflammatory effect,
inducing IL-12 by the DCs and subsequent activation of
NK cells to make IFN-␥.
Lastly, the requirement for DCs and NK cells was assessed.
Punctual depletion of DCs was performed by exploiting a
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context of allergy or asthma. Given this backdrop, the observation that other PAMs are known to have an enhancing
effect on diverse rodent models of inflammatory arthritis (7, 8),
and the precedent that CpGs, themselves, have been reported
to promote arthritis in more than one model (6, 25), we were
surprised to find that ODN1668 could block arthritis development in the K/BxN serum-transfer system. Even more
striking, ODN1668 is one of the few agents thus far found
to be capable of reversing ongoing arthritis in this system.
Our mechanistic studies afforded a second surprise. The original scenario constructed to account for the immunostimulatory
1918

activities of CpG-B-ODNs began with TLR9-signaled
activation of B and DCs and ended with a potent response
by the adaptive immune system, entailing Abs, TH1 cells, and
cytotoxic CD8+ T cells (Fig. 7 A) (9). More recently, this
scenario was enriched to include DC-induced stimulation
of NK cells, but it still culminated in and highlighted the
promotion of more effective T cell and Ab responses (24, 26).
Cases of CpG-ODNs dampening immune responses have been
described in the past—autoimmune (27–29), asthmatic (30),
or standard T cell (31)—in nature, but, in all of these studies,
data, or sometimes just mere assumption, focused attention on
ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
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Figure 6. DCs and NK cells are required for CpG-mediated protection. (A) DCs needed. (top left) Protocol for DC depletion and serum⫹ODN1668
treatment. DTR mice and littermate controls (Tg [−]) were injected with serum on day 0 and 2, followed by DT treatment on day 4; animals were treated
with ODN1668 or PBS on day 5. (bottom left) Flow cytometric analysis was performed on the splenic DC populations (CD11c⫹) of DTR mice after 20-h
treatment with DT. Tg (−) littermates treated with DT and DTR mice treated with PBS served as negative controls. (right) DC-deficient (DTR) mice treated
with serum⫹PBS or serum⫹CpG, or Tg (−) control littermates were monitored for arthritis progression. Average ankle thickening subsequent to day 0
(the commencement of CpG or PBS treatment) is plotted. DT-treated DTR mice with serum⫹PBS, n ⫽ 8; DT-treated DTR mice with serum⫹CpG, n ⫽ 8;
DT-treated Tg (-) mice with serum⫹PBS, n ⫽ 11; DT-treated Tg (-) mice with serum+CpG, n ⫽ 11. (B) NK cells needed. Mean ankle thickening of NK cell–
deficient (IL-15⫺/⫺) or WT mice after administration of K/BxN serum alone or with ODN1668 in addition. Results compiled from three independent
experiments with 8–9 mice/group. In a similar set-up, NK cell–deficient mice were generated by injection of anti–asialo-GM1 Ab (anti-GM1). Mean ankle
thickening of NK cell–deficient (anti-GM1) or control (normal Ig) mice after treatment with K/BxN serum alone on day 0 and 2 or with ODN1668 on day 0
in addition. n = 4 mice/group. (C) Cytokine consequences. IL-15⫺/⫺ and B6 mice, or DT-treated DTR animals, and their littermate controls were treated
with ODN1668 for 4 h. (For both DTR and control mice, ODN1668 was injected 20 h after DT treatment.) Fold induction of cytokine transcripts in splenocytes shown as IL-15⫺/⫺ verse WT, or DTR versus WT, respectively.
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contexts (34, 35). Another issue is that the various experiments did not always use the same CpG-ODN; sometimes
CpG-A versus -B, sometimes a different one of the many
available CpG-Bs. This element is a critical one, as we saw
from Fig. 1 B that even CpGs of the same class can have very
different effects in vivo. Third, the picture that emerges is
complicated by the difficulty for any study to be comprehensive in light of a constantly increasing cast of players. In this
respect, we have briefly explored the roles in CpG-mediated
protection of several elements that have elicited interest of
late, including the following: indoleamine 2,3-dioxygenase
(IDO) (31), interferon-producing killer DCs (IKDCs) (36),
and plasmacytoid DCs (pDCs). Under a dose of 1-methyltryptophan, which is an IDO inhibitor previously reported to
reverse the immunoresistance of IDO-expressing tumors (37),
we did not see any effect on CpG-mediated arthritis inhibition (Fig. S7). This result is consistent with the observation that the immunosuppressive effect of IDO is known to
work through T cells (31, 38), whereas CpG-mediated protection from arthritis is T cell–independent (Fig. S5). Likewise, the recently identified IKDC population may not have
a substantial role in our system, as the majority of NK1.1positive cells expanded after CpG treatment were CD11cnegative (Fig. S8). In contrast, we found that pDCs did have
a partial effect on CpG-mediated protection from arthritis
(Fig. S9). Ostensibly, this effect does not operate through the
NK–DC/IL-12–IFN-␥ axis we have focused on in this study,
as pDCs do not produce either of these two cytokines (Fig.
5 D). The role of pDC is instead through a secondary axis
involving Type I IFN (unpublished data). Lastly, existing

Figure 7. A comparison of proposed immunotherapeutic mechanisms of CpG. (A) The now classical CpG-mediated therapeutic mechanism involved activation of adaptive immunity, such as enhancement of Th1, CTL, and Ab response. This mechanism has been shown to play a key role in disease
protection in infection and tumor contexts (24). (B) More recent studies revealed an immunosuppressive effect of CpG. CpG-mediated suppression of an
undesired immune response was achieved by regulating acquired immunity in certain allergic reactions or autoimmune diseases. Some examples are
switching of a Th2 to a Th1 response (30), activating T regulatory T cells (31), and inducing Ig isotype switching (53). (C) The CpG-mediated therapeutic
mechanism proposed here is an antiinflammatory response that relies solely on cells of the innate immune system. ODN1668 signals through TLR9 on
CD8␣⫹DCs to induce IL-12 secretion; IL-12 promotes expression of IFN-␥ by NK cells. The process is amplified through a feed-forward loop entailing
DC-produced IL-12 and NK cell–produced IFN-␥; the resulting elevated systemic levels of IFN-␥ inhibit arthritis development by preventing neutrophil
recruitment into the joint.
JEM VOL. 204, August 6, 2007
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the response of the adaptive immune system (Fig. 7 B). In
contrast, the arthritis-inhibitory property of ODN1668 described in this study did not depend on either B or T cells, and
thereby reflected an influence solely on the operation of the
innate immune system (Fig. 7 C). The key turned out to be
cross talk between CD8␣⫹DCs and NK cells, which relied
critically and interdependently on IL-12 produced by the
former and IFN-␥ made (mostly) by the latter. The eventual
outcome of this “conversation” was suppression of the recruitment of neutrophils, a direct effect of IFN-␥ on that cell type.
At first glance, our data may also appear reminiscent of the
recent observations of Katakura et al. on experimental colitis
(32). However, these authors described only a protective
effect; in fact, when administered therapeutically, ODN1668
exacerbated colitis (33). Moreover, in this case, IFN-␥ was
pro- rather than antiinflammatory (33).
If one considers the extensive body of existing information on events downstream of CpG-ODN engagement of
TLR9 on immune cells, one is faced with a complex, oftenconflicting set of data (18, 19). An example is the differential
reliance on priming and facilitating cytokines, such as IL-2,
IL-15, IFN-␣/␤, and TNF-␣, to optimally activate NK cells.
Part of the difficulty in assessing and comparing results is that
many of them emanate from in vitro experiments on cells
derived from various tissues according to diverse expansion
protocols. For example, this factor could easily explain why
we saw no influence of IL-2 in either gain-of-function or
loss-of-function in vivo experiments (Fig. S6, available at
http://www.jem.org/cgi/content/full/jem.20070285/DC1),
although it appeared to have a critical role in certain in vitro
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MATERIALS AND METHODS
Mice. C57BL/6 (B6), B6.SJL (CD45.1⫹ congenic B6 mice), and NOD/Lt
(NOD) mice were purchased from The Jackson Laboratory. KRN TCRtransgenic mice, which were described elsewhere (50), were maintained on the
B6 genetic background (K/B6). Crossing K/B6 animals with NOD mice generated arthritic K/BxN offspring. H-2g7 congenic mice on the B6 background
(B6g7) were bred in our animal facility. The various gene-deficient mice are
described in the Supplemental materials and methods (available at http://www
.jem.org/cgi/content/full/jem.20070285/DC1). All mouse procedures were
conducted in compliance with federal and institutional guidelines.
Reagents. Reagents are described in the Supplemental materials and methods.
Serum-transfer system and evaluation of arthritis. Optimal serumtransferred arthritis was induced by i.p. injection of 100–150 l of pooled
serum from 8-wk-old K/BxN mice on days 0 and 2, unless otherwise mentioned. Suboptimal arthritis was induced by i.p. injection of 100 l K/BxN
serum on day 0. Ankle thickness was measured with a caliper (J15 Blet
micrometer). Each limb was scored on a scale from 0 (no observable swelling)
to 3 (severe inflammation), and the four-limb scores were summed to yield
a clinical index (maximum 12 points).
Histology. Ankle sections were stained with hematoxylin and eosin or with
CAE plus hematoxylin as a counterstain, as previously described (50, 51).
Neutrophils exhibited a red cytoplasmic staining with CAE, which is a
marker of the myeloid and mast cell lineages that does not stain monocytes,
macrophages, or basophils. Immunohistology methods are detailed in the
Supplemental materials and methods, with procedures carried out basically as
previously described (15).
Intravital confocal microscopy. Microscopy was performed as recently
published (11), and is detailed in the Supplemental materials and methods.
Neutrophil imaging: a laser-scanning, time-lapse intravital microscopy system. The imaging system for neutrophils is described in detail in
the Supplemental materials and methods.
ELISAs. Anti-GPI Ab titers were measured as previously described (52).
In brief, recombinant mouse GPI was coated on ELISA plates at 5 mg/ml,
and diluted mouse sera was added. Subsequently, alkaline phosphatase (AP)–
conjugated anti–mouse total IgG, followed by AP-conjugated streptavidin, was
applied. After substrate addition, titers were quantitated according to the
optimal density (OD) values from an ELISA reader. Serum levels of IL-12
and -23 were measured by an ELISA kit, using the instructions provided by
the company (eBioscience). Capture-Ab clones C18.2 (anti–IL-12p35) and
G23-8 (anti–IL-23p19) were specific for their respective cytokines. Both
detection systems used clone C17.8 as the detection Ab for the p40 subunit
shared by the two cytokines. Standard curves were generated using the
recombinant IL-12 or -23 provided by the kit.
Flow cytometry. Abs and flow cytometry techniques are described in the
Supplemental materials and methods.
Cell culture. An equal ratio of splenocytes from TLR9⫺/⫺ (CD45.2⫹) and
B6.SJL mice (CD45.1⫹) mice were cultured at 2 ⫻ 106/well in 96-well plates
with 1 M CpG. Cells were harvested after 2 or 4 h and sorted into WT or
TLR9⫺/⫺ DC and NK cell populations based on the CD45 alleles expressed.
NK cell depletion. Polyclonal rabbit anti–asialo-GM1 Ab (Cedarlane Laboratories) was used for in vivo depletion of NK cells. Mice were injected i.p.
with 50 μl of Ab on days 1, 2, 5, and 9 via serum injection or with an equivalent amount of rabbit gamma-globulin (The Jackson Laboratory).
RT-PCR. RNA was isolated from splenocytes via Trizol and reversetranscribed using oligo dT priming and Superscript polymerase (Invitrogen).
ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
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information comes from a mix of mouse and human studies and,
although the general outline is very similar in the two cases,
details of the scenario certainly diverge, reflecting species differences such as the precise cell types that express TLR9 (9).
One of the key elements in the CpG-mediated inhibitory
effect was IL-12. This dependence may explain the divergent
results with the other TLR ligands we tested, as CpG is a
much stronger IL-12 inducer than LPS or polyI:C (unpublished data) (39, 40). IFN-␥ is the other important molecule
mediating the protective effect. Systemic administration of
IFN-␥ prevented arthritis, and this effect appeared to be via
blockade of neutrophil recruitment to the joint. Neutrophils
were the direct targets of the IFN-␥–mediated inhibitory effect, as migration of those devoid of IFN-␥R was not inhibited. One attractive hypothesis for IFN-␥’s downstream
mode of action is through down-regulation of CXCR4, as
this cytokine has been described to control neutrophil migration in different contexts by posttranslational down-regulation
of this chemokine receptor (41, 42).
Why did CpG-ODNs dampen arthritis in the K/BxN
serum-transfer system, whereas they promoted disease in other
arthritis models (6, 25)? One explanation is that local CpG
injection (6) may be proinflammatory, but systemic delivery
antiinflammatory. Such behavior would parallel observations
on the effect of administering IFN-␥ in the collagen-induced
arthritis model; injection into the paw promoted disease, although back delivery was inhibitory (43, 44). An explanation in
another case (25) is that the influence of CpGs may differ according to when they are introduced, with the lymphocytemediated initiation phase being more prone to an enhancing
effect. One strength of the K/BxN serum-transfer system is
that it focuses uniquely on the effector phase mediated by
cells of the innate immune system, which is the phase when
most patients would present. Lastly, it may be relevant that
the K/BxN system does not entail other potentially synergistic
TLR ligands, such as adjuvant (25) or LPS (7).
We hope that our findings will be translatable to the
human arthritis context. Differences in TLR9 expression
(or other factors) between mice and humans may mean that
translation will not be entirely linear, but there should be
many commonalities in the molecules, cells, pathways, and
networks involved, so that their identification and characterization should provide points of access to the inhibitory
process beyond CpG-ODNs themselves. In this regard, it is
encouraging that the antiinflammatory properties of IFN-␥
are being increasingly appreciated and studied in both species, leading to the recognition that some of the critical
molecular mechanisms are shared, at least as far as can be
concluded from cell culture experiments (45). Also promising is that clinical trials of rhIFN-␥ in small cohorts of RA
patients in the 1980s and 1990s proved it safe, and usually
(46–48), but not always (49), somewhat effective. It may be
worth revisiting this strategy, or allied therapeutic strategies, especially if it becomes possible to phenotypically or
genetically stratify the patients most likely to have a beneficial response.
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Quantitative RT-PCR was performed on an Mx3000p instrument (Stratagene), using gene-specific fluorogenic assays (TaqMan; Applied Biosystems).
Primers and probes are listed in the Supplemental materials and methods.
The cytokine transcripts in spleens were quantitated by RT-PCR using hypoxanthine guanine phosphoribosyl transferase mRNA as an internal standard.
Fold induction represents relative expression levels of cytokine transcripts
from CpG-ODN–treated mice standardized against the level of cytokine
transcripts from untreated B6 mice.
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